Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells

Biochemical Pharmacology

Volumn 65, Issue 7, 2003, Pages 1053-1060

  Liang, Yu Chih ^a,b   Tsai, Shu Huei ^a   Chen, Linda ^a   Lin Shiau, Shoei Yn ^a   Lin, Jen Kun ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CDC25A; CDK7; Cell cycle; p34CDC2; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 7; PHOSPHATASE; PROTEIN KINASE; RESVERATROL; CDC25A PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE; PROTEIN TYROSINE PHOSPHATASE; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL DISRUPTION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING; CELL CULTURE; CELL DIVISION; CELL STRAIN HT29; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASE; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASES; G2 PHASE; HT29 CELLS; HUMANS; STILBENES; TUMOR CELLS, CULTURED;

EID: 0037378391     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00011-X     Document Type: Article

References (42)

1. Dercks W., Creasy L.L. Influence of fosetyl-AL on phytoalexin accumulation in the plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Pathol. 34:1989;203-213.
2. Soleas G.J., Diamandis E.P., Goldberg D.M. Resveratrol: a molecule whose time has come? And gone? Clin. Biochem. 30:1997;91-113.
3. Fontecave M., Lepoivre M., Elleingand E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:1998;277-279.
4. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H.S., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
5. Mgbonyebi O.P., Russo J., Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12:1998;865-869.
6. Carbó N., Costelli P., Baccino F.M., López-Soriano F.J., Argilés J.M. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun. 254:1999;739-743.
7. Clément M.V., Hirpara J.L., Chawdhury S.H., Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 92:1998;996-1002.
8. Pace-Asciak C.R., Hahn S., Diamandis E.P., Soleas G., Goldberg D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 235:1995;207-219.
9. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273:1998;21875-21882.
10. Tsai S.H., Lin-Shiau S.Y., Lin J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br. J. Pharmacol. 126:1999;673-680.
11. Nurse P. Universal control mechanism regulating onset of M-phase. Nature. 344:1990;503-508.
12. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
13. Labbé J.C., Capony J.P., Caput D., Cavadore J.C., Derancourt J., Kagha M., Lelias J.M., Picard A., Dorée M. MPF from starfish oocytes at first meiotic metaphase is a heterodimer containing one molecule of cdc2 and one molecule of cyclin B. EMBO J. 8:1989;3053-3058.
14. Gautier J., Minshull J., Lohka M., Glotzer M., Hunt T., Maller J.L. Cyclin is a component of maturation-promoting factor from Xenopus. Cell. 60:1990;487-494.
15. Whitfield W.G.F., Gonzáles C., Sánchez-Herrero E., Glover D.M. Transcripts of one of two Drosophila cyclin genes become localized in pole cells during embryogenesis. Nature. 338:1989;337-340.
16. Hunt T. Maturation promoting factor, cyclin and the control of M-phase. Curr. Opin. Cell Biol. 1:1989;268-274.
17. cdc2 function. EMBO J. 10:1991;3297-3309.
18. cdc2 activation: identification of an activating kinase. Mol. Biol. Cell. 3:1992;13-27.
19. + protein kinase regulates entry into mitosis. Nature. 342:1989;39-45.
20. cdc2 protein kinase in vertebrates. EMBO J. 10:1991;3321-3329.
21. cdc2. EMBO J. 12:1993;3123-3132.
22. MO15. EMBO J. 12:1993;3133-3142.
23. Fesquet D., Labbé J.C., Derancourt J., Capony J.P., Galas S., Girard F., Lorca T., Shuttleworth J., Dorée M., Cavadore J.C. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J. 12:1993;3111-3121.
24. cdc2 kinase in fission yeast. EMBO J. 10:1991;4301-4309.
25. Kumagi A., Dunphy W.G. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell. 64:1991;903-914.
26. cdc2. Cell. 67:1991;197-211.
27. cdc2/cyclin B complex in vitro by human CDC25 protein. Nature. 351:1991;242-244.
28. cdc2 cell cycle-regulated protein kinases is required to initiate mitosis in A. nidulans. Cell. 67:1991;283-291.
29. Spinozzi F., Pagliacci M.C., Migliorati G., Maraca R., Grignani F., Riccardi C., Nicoletti I. The natural tyrosine kinase inhibitor genistein products cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk. Res. 18:1994;431-439.
30. Traganos F., Ardelt B., Halko N., Bruno S., Darzynkiewicz Z. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res. 52:1992;6200-6208.
31. Yoshida M., Sakai T., Hosokawa N., Marui N., Matsumoto K., Fujioka A., Nishino H., Aoike A. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 260:1990;10-13.
32. Wang I.K., Lin-Shiau S.Y., Lin J.K. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur. J. Cancer. 35:1999;1517-1525.
33. Huang T.S., Shu C.H., Yang W.K., Whang-Peng J. Activation of CDC25 phosphatase and CDC2 kinase involved in GL331-induced apoptosis. Cancer Res. 57:1997;2974-2978.
34. Liang Y.C., Lin-Shiau S.Y., Chen C.F., Lin J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J. Cell. Biochem. 75:1999;1-12.
35. Ries L.A., Wingo P.A., Miller D.S., Howe H.L., Weir H.K., Rosenberg H.M., Vernon S.W., Cronin K., Edwards B.K. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 88:2000;2398-2424.
36. Harris C.C. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1996;1187-1198.
37. Steele V.E., Moon R.C., Lubet R.A., Grubbs C.J., Reddy B.S., Wargovich M., McCormick D.L., Pereira M.A., Crowell J.A., Bagheri D., Sigman C.C., Boone C.W., Kelloff G.J. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from NCI Chemoprevention Drug Development Program. J. Cell Biochem. Suppl. 20:1994;32-54.
38. Schatzkin A., Kelloff G. Chemo- and dietary prevention of colorectal cancer. Eur. J. Cancer. 31A:1995;1198-1204.
39. Lu R., Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179:1999;297-304.
40. 2 phase transition. Biochem. Biophys. Res. Commun. 250:1998;53-58.
41. 2. Cancer Res. 59:1999;2596-2601.
42. 2/M transition. Cancer Surv. 29:1997;47-73.